GlassScriptPhysician profile
Marc C Peden
NPI 1316028335
$42,861.88
in general payments reported to CMS, 2019-2025
25 companies · $1,622 in 2025
The $1,622 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $4,412 · 2021: $1,316 · 2022: $3,756 · 2023: $10K · 2024: $4,546 · 2025: $1,622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,990 · Food and Beverage: $7,219 · Travel and Lodging: $395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,990.00 |
| Food and Beverage | $7,218.68 |
| Travel and Lodging | $394.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $29,497.02 | 2019-2025 | Vabysmo, Susvimo, Lucentis |
| Eyepoint US, INC. | $4,057.92 | 2020-2024 | |
| Bausch & Lomb Americas INC. | $2,070.64 | 2022-2025 | Xipere, Visudyne |
| Regeneron Healthcare Solutions, INC. | $1,381.98 | 2019-2025 | Eylea Hd, Eylea |
| Regeneron Pharmaceuticals, INC. | $1,147.07 | 2022-2025 | Eylea Hd, Eylea |
| Alimera Sciences, INC. | $1,122.89 | 2019-2024 | Iluvien, Yutiq |
| Apellis Pharmaceuticals, INC. | $764.01 | 2022-2025 | Syfovre |
| Horizon Therapeutics Plc | $330.07 | 2021-2023 | Tepezza |
| Allergan, INC. | $278.43 | 2019-2021 | |
| Alcon Vision LLC | $272.92 | 2020-2025 | Constellation |
| Genentech, INC. | $267.78 | 2019 | |
| Ocular Therapeutix, INC. | $213.96 | 2023-2024 | Dextenza |
| Carl Zeiss Meditec, INC. | $189.30 | 2021 | |
| Novartis Pharmaceuticals Corporation | $172.33 | 2019-2021 | |
| Sandoz INC. | $160.99 | 2024-2025 | Cimerli |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $158.14 | 2023-2025 | Izervay |
| Kala Pharmaceuticals, INC. | $148.44 | 2019-2021 | |
| Abbvie INC. | $125.00 | 2024 | |
| Coherus Oncology, INC. | $115.21 | 2023-2024 | |
| Ani Pharmaceuticals, INC. | $113.35 | 2023-2025 | Iluvien, Purified Cortrophin Gel, Yutiq |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $105.05 | 2019-2021 | |
| Biogen, INC. | $98.83 | 2023 | |
| Sun Pharmaceutical Industries INC. | $24.50 | 2020 | |
| Cardinal Health 108 LLC | $24.00 | 2025 | |
| Johnson & Johnson Surgical Vision, INC. | $22.05 | 2023 | Tecnis Iol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Peden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.